CGEN
Undervalued by 42.8% based on the discounted cash flow analysis.
Market cap | $155.23 Million |
---|---|
Enterprise Value | $153.05 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-0.16 |
Beta | 2.55 |
Outstanding Shares | 92,308,225 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -10.83 |
---|---|
PEG | 915.38 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | 5.55 |
Enterprise Value to EBIT | -10.35 |
Enterprise Value to Net Income | -11 |
Total Debt to Enterprise | 0.08 |
Debt to Equity | 0.22 |
No data
No data
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...